The addition of atezolizumab to BCG did not yield improved EFS compared with BCG alone in patients with high-risk non–muscle-invasive bladder cancer.

QUILT 3.032 study completes planned enrollment of BCG unresponsive non-muscle invasive bladder cancer CIS cohort with 59% probability of patients maintaining complete response for at least 12 months ...

Binah Capital Group ( ($BCG) ) has shared an update. On December 1, 2025, Binah Capital Group announced an investor presentation to be used at the ...

CULVER CITY, Calif.--(BUSINESS WIRE)--ImmunityBio, Inc., a privately-held immunotherapy company, today announced the oral presentation of “Phase II/III clinical results of IL-15RαFc superagonist N-803 ...